MTHFR and myeloid sarcoma: Meta-analysis showed a statistical significance between the MTHFR 1298 A/C polymorphism and the presence of MS in overall analysis (AC vs. AA: OR = 2.36, 95% CI, 1.29-4.30; AC/CC vs. AA: OR = 2.31, 95% CI, 1.24-4.29, respectively) and subgroup analysis, such as high-quality studies (AC vs. AA: OR = 4.64, 95% CI, 1.08-19.88) and low-quality studies (AC vs. AA: OR = 1.50, 95% CI, 1.05-2.15; AC/CC vs. AA: OR = 1.50, 95% CI, 1.09-2.07, respectively) (Table 3).